Here's Why You Should Add HAE Stock in Your Portfolio Now

Haemonetics Corporation (HAE) is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company's Hemostasis Management franchise is evolving and helping create new opportunities for growth and diversification. Strong financial stability also buoys optimism. Meanwhile, headwinds from adverse foreign exchange effects pose concern to Haemonetics' operations. In the past year, this Zacks Rank #2 (Buy) company has lost 14.5% against the industry's 24.6% growth an ...